Agios Pharmaceuticals Inc. said David Schenkein will step down as CEO on Feb. 1, 2019 and become executive chairman of the board.
Schenkein has served as CEO of the Cambridge, Mass.-based company since 2009 and oversaw the U.S. approval of two cancer medicines.
Jacqualyn Fouse, who joined Agios' board in December 2017, will succeed Schenkein as CEO. She will remain on the board of directors.
Fouse previously worked as president and COO of Summit, N.J.-based biopharmaceutical company Celgene Corp.
Further, Agios Chairman John Maraganore will become a director when Schenkein becomes chairman.